Drugs for Leiner Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):
(show all 50)
# |
|
Name |
Status |
Phase |
Clinical Trials |
Cas Number |
PubChem Id |
1 |
|
Emollients |
|
Phase 4 |
|
|
|
2 |
|
Dermatologic Agents |
|
Phase 4 |
|
|
|
3 |
|
Trametinib |
Approved |
Phase 2 |
|
871700-17-3 |
11707110
|
Synonyms:
GSK1120212
JTP-74057
MEK Inhibitor GSK1120212
Mekinist
|
trametinib
Trametinib
Tramétinib
Trametinibum
|
|
4 |
|
Carboplatin |
Approved |
Phase 2 |
|
41575-94-4 |
10339178
38904
498142
|
Synonyms:
(SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O']platinum
/h1-3H2,(H,7,8)(H,9,10)
/q
1,1-Cyclobutanedicarboxylate diammine platinum (II)
1,1-Cyclobutanedicarboxylate diammine platinum(II)
2*-1
2*1H2
41575-94-4
70903-55-8
AC-1457
AC1L8I6U
Ambap41575-94-4
azanide
Blastocarb
BSPBio_003145
C 2538
C2043
C2538_SIGMA
C6H10N2O4Pt
Carbopaltin
Carboplat
carboplatin
Carboplatin
Carboplatin (JAN/USP/INN)
Carboplatin (USAN)
Carboplatin [USAN:INN:BAN:JAN]
Carboplatine
Carboplatine [French]
Carboplatino
Carboplatino [Spanish]
Carboplatinum
Carboplatinum [Latin]
Carbosin
Carbotec
Cbdca
CBDCA
CCRIS 3404
CHEBI:31355
CHEMBL1351
CHEMBL288376
CID10339178
CID2567
CID38904
CID426756
CID498142
CID5352133
CID6398587
CID6603770
cis -Diammine[1,1-cyclobutane-dicarboxylato] platinum
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(ii)
cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II)
cis-Diamine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II)
cis-Diammine(1,1-cyclobutanedicarboxylato) platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum
cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)
cis-Diammine(cyclobutanedicarboxylato)platinum II
Cyclobutane-1,1-dicarboxylate
cyclobutane-1,1-dicarboxylic acid
D01363
DB00958
Diammine(1,1-cyclobutanedicarboxylato)platinum (II)
Diammine(cyclobutane-1,1-dicarboxylato(2-)-O,O')platinum
diammine[cyclobutane-1,1-dicarboxylato(2-)-k2O1,O1]platinum
Diammine-1,1-cyclobutane dicarboxylate platinum II
DivK1c_000892
|
EINECS 255-446-0
Ercar
EU-0100230
HMS1921J16
HMS2090M05
HMS2092B22
HMS502M14
HSDB 6957
I14-2390
IDI1_000892
InChI=1/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6
IUPAC: Azane
JM 8
JM8
JM-8
KBio1_000892
KBio2_002009
KBio2_004577
KBio2_007145
KBio3_002645
KBioGR_000713
KBioSS_002009
Lopac0_000230
Lopac-C-2538
LS-117689
MolPort-003-665-501
MolPort-003-845-609
NCGC00015223-01
NCGC00093695-01
NCGC00094961-01
NCGC00094961-02
NCGC00094961-03
NCGC00162099-01
NCGC00162099-02
NCGC00167800-01
NCGC00178242-01
nchembio.573-comp10
nchembio773-comp2
nchembio873-comp3
Nealorin
Neocarbo
NINDS_000892
NSC 201345
NSC 241240
NSC201345
NSC241240
NSC-241240
Paraplatin
Paraplatin (TN)
Paraplatin, Carboplatin
Paraplatin-AQ
Platinum(+2) Cation
platinum(2+)
Platinum(II), (1, 1-cyclobutanedicar
Platinum, {diammine[1,1-cyclobut
Platinum, diammine(1,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)
Ribocarbo
S1215_Selleck
SPBio_000716
Spectrum_001529
SPECTRUM1502106
Spectrum2_000898
Spectrum3_001503
Spectrum4_000337
Spectrum5_001094
UNII-BG3F62OND5
|
|
5 |
|
Gemcitabine |
Approved |
Phase 2 |
|
95058-81-4 |
60750
|
Synonyms:
103882-84-4
122111-03-9
2',2'-DFDC
2',2'-DiF-dC
2',2'-difluoro-2'-Deoxycytidine
2',2'-Difluoro-2'-deoxycytidine
2',2'-Difluorodeoxycytidine
2'-Deoxy-.beta.-D-2',2'-difluorocytidine
2'-Deoxy-2',2'-difluorocytidine
2'-Deoxy-2',2''-difluorocytidine-5'-O-monophosphate
2'-Deoxy-2'-difluorocytidine
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-amino-1-((2R,4R,5R)-3,3-difluoro-4-Hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-amino-1-((2R,4R,5R)-3,3-Difluoro-4-hydroxy-5-(hydroxymethyl)-tetrahydrofuran-2-yl)pyrimidin-2(1H)-one
4-Amino-1-[(2R,4R,5R)-3,3-difluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
4-Amino-1-[3,3-difluoro-4-hydroxy-5-(hydroxymethyl) tetrahydrofuran-2-yl]-1H-pyrimidin-2-one
95058-81-4
AB1004842
AC1L1TUQ
C07650
CCRIS 8984
CHEBI:175901
CHEMBL888
CID60750
Cytidine, 2'-deoxy-2',2'-difluoro-2'-Deoxy-.beta.-D-2',2'-difluorocytidine
D02368
DB00441
DDFC
DFdC
DFDC
DFdCyd
Folfugem
Gamcitabine
Gemcel
Gemcin
Gemcitabin
|
Gemcitabina
Gemcitabina [INN-Spanish]
gemcitabine
Gemcitabine
Gemcitabine (USAN/INN)
Gemcitabine HCl
Gemcitabine hydrochloride
Gemcitabine stereoisomer
Gemcitabine, (alpha-D-threo-pentofuranosyl)-isomer
Gemcitabine, (beta-D-threo-pentafuranosyl)-isomer
Gemcitabine, (D-threo-pentafuranosyl)-isomer
Gemcitabinum
Gemcitabinum [INN-Latin]
GemLip
Gemtro
Gemzar
Gemzar (hydrochloride)
GEO
HMS2089P10
HSDB 7567
Inno-D07001
LS-59139
LY 188011
LY188011
LY-188011
NCGC00168784-01
NChemBio.2007.10-comp25
nchembio.573-comp7
nchembio.90-comp2
NSC 613327
NSC613327
TL8005979
UNII-B76N6SBZ8R
Zefei
ZINC18279854
|
|
6 |
|
Cisplatin |
Approved |
Phase 2 |
|
15663-27-1 |
2767
441203
84093
|
Synonyms:
(SP-4-1)-diamminedichloridoplatinum
(SP-4-1)-diamminedichloroplatinum
(SP-4-2)-diamminedichloridoplatinum
(SP-4-2)-diamminedichloroplatinum
Abiplatin
Biocisplatinum
Briplatin
CACP
Carboquone
CDDP
CHEBI:35852
CID441203
Cis Pt II
cis-[PtCl2(NH3)2]
cis-DDP
Cis-DDP
Cis-Diaminedichloroplatinum
cis-diamminedichloridoplatinum(II)
cis-Diamminedichloroplatinum
Cis-Diamminedichloroplatinum
cis-diamminedichloroplatinum(II)
cis-Dichlorodiammineplatinum(II)
Cismaplat
Cisplatine
cisplatino
Cisplatino
Cisplatinum
Cisplatyl
Citoplationo
CPD0-1392
CPDC
|
CPDD
DB00515
DDP
DDPT
Diamminedichloroplatinum
EU-0100918
Lederplatin
nchembio773-comp1
Neoplatin
Peyrone's chloride
Peyrone's salt
Plastin
Platamine
Platiblastin
Platidiam
Platinex
Platinol
Platinol-AQ
Platinoxan
Platinum Ammine Chloride
Platinum Ammonium Chloride
Platinum Diamine Dichloride
Randa
trans-DDP
Trans-DDP
Trans-Diaminedichloroplatinum
trans-diamminedichloridoplatinum(II)
Trans-Diamminedichloroplatinum
Trans-Dichlorodiammine Platinum
Trans-Platinumdiammine Dichloride
|
|
7 |
|
Mechlorethamine |
Approved, Investigational |
Phase 2 |
|
51-75-2 |
4033
|
Synonyms:
.Beta.,.beta.'-Dichlorodiethyl-N-methylamine
1, 5-Dichloro-3-methyl-3-azapentane hydrochloride
126-85-2 (N-oxide)
2,2'-Dichlorodiethyl-methylamine
2,2'-Dichloro-N-me
2,2'-dichloro-N-methyldiethylamine
2,2'-dichloro-N-Methyldiethylamine
2,2'-Dichloro-N-methyldiethylamine
2-Chloro-N-(2-chloroethyl)-N-methylethanamine
302-70-5 (N-oxide, hydrochloride)
51-75-2
55-86-7 (HYDROCHLORIDE)
AC1L1H9H
Antimit
b,Beta'-dichlorodiethyl-N-methylamine
beta,beta'-Dichlorodiethyl-N-methylamine
beta,Beta'-dichlorodiethyl-N-methylamine
Bis(2-chloroethyl)methylamine
Bis(b-chloroethyl)methylamine
Bis(beta-chloroethyl) methylamine
Bis(beta-chloroethyl)methylamine
Bis(β-chloroethyl)methylamine
BRN 0605323
BSPBio_001947
C07115
C5H11Cl2N
Carolysine
Caryolysin
Caryolysine
CCRIS 447
CHEBI:28925
CHEMBL427
Chloramine (the nitrogen mustard)
Chlorethazine
Chlormethine
Chlormethine (INN)
Chlormethine [INN:BAN]
Chlormethinum [INN-Latin]
CID4033
Cloramin
Clormetina
Clormetina [INN-Spanish]
D07671
DB00888
Di(2-chloroethyl)methylamine
Dichlor amine
Dichloren
DivK1c_000759
EINECS 200-120-5
Embechine
Embichin
ENT-25294
HMS1920J15
HMS2091B04
HMS502F21
HN2
HN-2
HSDB 5083
Hydrochloride N-oxide, mechlorethamine
Hydrochloride, mechlorethamine
I14-8708
IBS-L0033631
IDI1_000759
KBio1_000759
KBio2_001369
KBio2_003937
KBio2_006505
KBio3_001447
KBioGR_001448
KBioSS_001369
LS-7559
MBA
Me chloroethamine
Mebichloramine
mechlorethamine
|
Mechlorethamine
Mechlorethamine hydrochloride
Mechlorethamine hydrochloride N oxide
Mechlorethamine hydrochloride N-oxide
Mechlorethamine N oxide
Mechlorethamine N-oxide
Mechlorethamine oxide
Mechlorethanamine
Mechloroethamine
Mecloretamina
Mecloretamina [Italian]
Merck brand OF mechlorethamine hydrochloride
Merck frosst brand OF mechlorethamine hydrochloride
Methylbis(2-chloroethyl)amine
Methylbis(b-chloroethyl)amine
Methylbis(beta-chloroethyl)amine
Methylbis(β-chloroethyl)amine
Methylchlorethamine
Methyldi(2-chloroethyl)amine
Mitomen
Mitoxine (*Hydrochloride*)
MolPort-001-785-592
Mustargen
Mustine
Mustine note
Mutagen
N,N-Bis(2-chloroethyl)methylamine
N,N-Bis(2-chloroethyl)-N-methylamine
N,N-Di(chloroethyl)methylamine
NCGC00091835-02
NCGC00091835-03
NCGC00091835-04
NCGC00091835-05
NCI60_041682
NINDS_000759
Nitol (*Hydrochloride*)
Nitrogen mustard
Nitrogen mustard (HN-2)
Nitrogen mustard N oxide
Nitrogen mustard N-oxide
Nitrogranulogen
Nitromin
N-Lost
N-Methyl lost
N-Methyl-2,2'-dichlorodiethylamine
N-methyl-bis(2-chloroethyl)amine
N-Methyl-bis(2-chloroethyl)amine
N-Methyl-bis(b-chloroethyl)amine
N-Methyl-bis(beta-chloroethyl)amine
N-Methyl-bis(β-chloroethyl)amine
N-Methyl-bis-chloraethylamin
N-Methyl-bis-chloraethylamin [German]
N-Methyl-lost
N-Methyl-lost [German]
N-Oxide, mechlorethamine hydrochloride
N-Oxide, nitrogen mustard
NSC 762
NSC762
NSC-762
SPBio_000496
Spectrum_000889
SPECTRUM1500375
Spectrum2_000448
Spectrum3_000484
Spectrum4_000924
Spectrum5_001702
Stickstofflost (*Hydrochloride*)
Stickstofflost (ebewe)
T 1024
T-1024
thyldiethylamine
TL 146
UNII-50D9XSG0VR
β,beta'-dichlorodiethyl-N-methylamine
β,β'-dichlorodiethyl-N-methylamine
|
|
8 |
|
rituximab |
Approved |
Phase 2 |
|
174722-31-7 |
10201696
|
Synonyms:
AntiCD20
IDEC-102
IDEC-C2B8
Ig gamma-1 chain C region
|
Mabthera
MabThera
Rituxan
rituximab
|
|
9 |
|
Ofatumumab |
Approved |
Phase 2 |
|
679818-59-8 |
6918251
|
Synonyms:
Arzerra
HuMax-CD20
ofatumumab
|
|
|
10 |
|
Tremelimumab |
Investigational |
Phase 2 |
|
745013-59-6 |
|
Synonyms:
|
11 |
|
Protein Kinase Inhibitors |
|
Phase 2 |
|
|
|
12 |
|
Complement System Proteins |
|
Phase 2 |
|
|
|
13 |
|
Antibodies, Monoclonal |
|
Phase 2,Phase 1 |
|
|
|
14 |
|
Immunologic Factors |
|
Phase 2,Phase 1 |
|
|
|
15 |
|
Immunoglobulin G |
|
Phase 2 |
|
|
|
16 |
|
Nitrogen Mustard Compounds |
|
Phase 2 |
|
|
|
17 |
|
Bendamustine Hydrochloride |
|
Phase 2 |
|
|
|
18 |
|
Alkylating Agents |
|
Phase 2 |
|
|
|
19 |
|
Antibodies |
|
Phase 2,Phase 1 |
|
|
|
20 |
|
Immunoglobulins |
|
Phase 2,Phase 1 |
|
|
|
21 |
|
Antineoplastic Agents, Alkylating |
|
Phase 2 |
|
|
|
22 |
|
Complement C3 |
|
Phase 2 |
|
|
|
23 |
|
Vaccines |
|
Phase 2,Phase 1 |
|
|
|
24 |
|
Everolimus |
Approved |
Phase 1 |
|
159351-69-6 |
6442177
|
Synonyms:
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone
(1R,9S,12S,15R,16E,23S,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriacont
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34as)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethy
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
(3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
001, RAD
07741_FLUKA
159351-69-6
40-O-(2-hydroxyethyl)-rapamycin
40-O-(2-Hydroxyethyl)-rapamycin
42-O-(2-Hydroxyethyl)rapamycin
Afinitor
Certican
CERTICAN(R)
CHEMBL1201755
D02714
DB01590
everolimus
|
Everolimus
Everolimus (JAN/USAN/INN)
Everolimus [USAN]
LS-143292
MolPort-003-847-342
MolPort-003-925-588
NCGC00167512-01
NVP-RAD-001
RAD 001
RAD, SDZ
RAD001
RAD-001
RAD001, SDZ-RAD, Certican, Zortress, Afinitor, Everolimus
RAD-001C
S1120_Selleck
SDZ RAD
SDZ-RAD
UNII-9HW64Q8G6G
Zortress
|
|
25 |
|
Sirolimus |
Approved, Investigational |
Phase 1 |
|
53123-88-9 |
46835353
6436030
5284616
|
Synonyms:
(-)-rapamycin
(-)-Rapamycin
1fkb
1pbk
23,27-Epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine
23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine
23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29
3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone
53123-88-9
A422989, NSC226080
AC1L1JH9
AC1L7MJ9
AC1L9ZMV
AC-722
Ambotz53123-88-9
Antibiotic AY 22989
AY 22989
AY22989
AY-22989
BIDD:PXR0165
Bio1_000293
Bio1_000782
Bio1_001271
Bio2_000375
Bio2_000855
BiomolKI2_000084
C07909
C51H79NO13
CBiol_002007
CCRIS 9024
CHEBI:100923
CHEBI:9168
CHEMBL413
CID10213190
CID10795871
CID11949238
CID11959112
CID313006
CID478951
CID5040
CID5284616
CID5358081
CID5374464
CID5460439
CID5497196
CID5924240
CID6436030
CID6610270
CID6610346
CID6711160
CID6713081
CID9833581
CID9854379
CID9854380
CID9962926
CID9962928
D00753
DB00877
DE-109
DivK1c_006936
FT-0082351
heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy
|
HMS2089A21
HSDB 7284
KBio1_001880
KBio2_000410
KBio2_002978
KBio2_005546
KBio3_000779
KBio3_000780
KBioGR_000410
KBioSS_000410
LCP-Siro
LMPK06000003
LS-143290
MLS000028373
MolMap_000043
MolPort-003-959-433
MS-R001
NCGC00021305-05
nchembio.100-comp4
nchembio.2007.42-comp2
nchembio.79-comp1
nchembio762-comp1
nchembio883-comp3
NCI60_001851
NCIMech_000355
NSC 226080
NSC226080
Perceiva
QTL1_000069
R0395_SIAL
R0395_SIGMA
RAP
RAPA
Rapammune
Rapamune
Rapamune (TN)
rapamycin
Rapamycin
Rapamycin (TN)
Rapamycin C-7, analog 4
Rapamycin from Streptomyces hygroscopicus
Rapamycin Immunosuppressant Drug
RPM
S1039_Selleck
SIIA 9268A
SILA 9268A
SILA9268A
sirolimus
Sirolimus
sirolimús
Sirolimus (RAPAMUNE)
Sirolimus (USAN/INN)
Sirolimus [USAN:BAN:INN]
Sirolimus, Rapamune,Rapamycin
sirolimusum
SMP1_000255
SMR000058564
SpecPlus_000840
UNII-W36ZG6FT64
UNM-0000358684
Wy 090217
WY-090217
|
|
26 |
|
Coal tar |
Approved |
Phase 1 |
|
8007-45-2 |
|
Synonyms:
|
27 |
|
Nivolumab |
Approved |
Phase 1 |
|
946414-94-4 |
|
Synonyms:
|
28 |
|
Oxaliplatin |
Approved, Investigational |
Phase 1 |
|
61825-94-3 |
43805
6857599
5310940
9887054
|
Synonyms:
CHEMBL1201055
CID9887054
D01790
DACPLAT
Diaminocyclohexane Oxalatoplatinum
Eloxatin
Eloxatin (TN)
Elplat
Foloxatine
L-OHP
Oxalatoplatin
Oxalatoplatinum
|
oxaliplatin
Oxaliplatin (JAN/USAN/INN)
Oxaliplatin [Usan:Inn:Ban]
oxaliplatine
oxaliplatino
Oxaliplatino [Spanish]
oxaliplatinum
Oxaliplatinum [Latin]
Oxaloplatine [French]
Oxaloplatino [Spanish]
Transplatin
|
|
29 |
|
Bevacizumab |
Approved, Investigational |
Phase 1 |
|
216974-75-3 |
|
Synonyms:
216974-75-3
antiVEGF
anti-VEGF monoclonal antibody
Avastin
Avastin (TN)
bevacizumab
|
Bevacizumab
Bevacizumab (genetical recombination)
Bevacizumab (genetical recombination) (JAN)
bevacizumab-awwb
D06409
R-435
|
|
30 |
|
Trifluridine |
Approved, Investigational |
Phase 1 |
|
70-00-8 |
6256
|
Synonyms:
1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-(trifluoromethyl)pyrimidine-2,4-dione
2'-Deoxy-5-(trifluoromethyl)uridine
2'-Deoxy-5-trifluoromethyluridine
5 Trifluoromethyl 2' deoxyuridine
5-(Trifluoromethyl)-2'-deoxyuridine
5-(Trifluoromethyl)deoxyuridine
5-Trifluoro-2'-deoxythymidine
5-Trifluoromethyl-2'-deoxyuridine
5-Trifluoromethyl-2-deoxyuridine
5-Trifluorothymidine
70-00-8
AC1L1M4O
Allergan brand OF trifluridine
alpha,alpha,alpha-Trifluorothymidine
BRN 0568095
C10H11F3N2O5
CCRIS 2348
CF3dUrd
CHEBI:269321
CHEMBL1129
CID6256
D00391
DB00432
EINECS 200-722-8
Elcon brand OF trifluridine
F3DThd
F3T
F₃T
F3TDR
Fluridine
FT-0082240
HS-0007
LS-153788
Mann brand OF trifluridine
MLS000028361
MLS001148248
|
Monarch brand OF trifluridine
NSC 529182
NSC 75520
NSC529182
NSC75520
S1778_Selleck
SMR000058583
T2255_SIGMA
T2511
TFDU
TFT
TFT Ophtiole
tramedico Brand OF trifluridine
Triflumann
Trifluoridine
Trifluoromethyldeoxyuridine
Trifluorothymidine
TRIFLUOROTHYMIDINE
trifluorothymine deoxyriboside
Trifluorothymine deoxyriboside
Trifluridin
Trifluridina
Trifluridina [INN-Spanish]
Trifluridine
Trifluridine (USP/INN)
Trifluridine [USAN:INN]
Trifluridinum
Trifluridinum [INN-Latin]
UNII-RMW9V5RW38
Viromidin
Virophta
Viroptic
Viroptic (TN)
Viroptic, Trifluorothymidine, Trifluridine
ZINC03842753
|
|
31 |
|
Vitamin A |
Approved, Nutraceutical, Vet_approved |
Phase 1 |
|
11103-57-4, 68-26-8 |
445354
|
Synonyms:
(11-cis,13-cis)-Retinol acetate
(13cis)-Retinol
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol
(2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohexen-1-yl)nona-2,4,6,8-tetraen-1-ol
(2Z,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol
(all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
.alpha.lin
.alpha.sterol
.beta.-Retinol
[11,12-3H]-Retinol
11,13-Di-cis-vitamin a acetate
11103-57-4
11-cis-13-cis-Retinol acetate
11-cis-13-cis-Retinyl acetate
13123-33-6
1341-18-0
1406-67-3
17104-91-5
1rbp
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclchexen-1-yl)-2,4,6,8-nonatetraen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonate-traen-1-ol
3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol, (all-E)-Isomer
3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)-2,4,6,8-nonatetraen-1-ol
4-06-00-04133 (Beilstein Handbook Reference)
53637-36-8
5979-23-7
68-26-8
95144_FLUKA
95144_SIGMA
95146_FLUKA
95146_SIGMA
AC-11701
AC1L9HU3
AC1Q7BU9
ACON
Afaxin
Agiolan
Agoncal
Alcohol 9,13-dimethyl-7-(1,1,5-trimethyl-6-cyclohexen-5-yl)-7,9,11,13-nonatetraen-15-ol
Alcovit A
alin
All Trans Retinol
All-trans retinol
ALL-TRANS RETINOL (SEE ALSO RETINOID PROJECT 1)
all-trans-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol
all-trans-retinol
all-trans-Retinol
all-trans-retinyl alcohol
all-trans-Retinyl alcohol
all-trans-Vitamin A
all-trans-vitamin A alcohol
all-trans-Vitamin A alcohol
all-trans-Vitamin A1
Alphalin
Alphasterol
A-Mulsal
Anatola
Anatola A
Anti-infective vitamin
Antixerophthalmic vitamin
Antixerophthalmisches Vitamin
Aoral
Apexol
Apostavit
Aquasol A Parenteral
Aquasynth
AR-1L3057
A-Sol
Atars
ATAV
Avibon
A-Vi-Pel
Avita
A-Vitan
Avitol
Axerol
Axerophthol
Axerophtholum
Bentavit A
beta-Retinol
BIDD:PXR0102
Biosterol
BRN 0403040
C00473
C17276
C20H30O
CCRIS 5444
CHEBI:17336
CHEMBL986
Chocola A
CID445354
Cylasphere
D014801
D06543
DB00162
Del-VI-A
Disatabs Tabs
Dofsol
Dohyfral A
EINECS 200-683-7
EINECS 234-328-2
Epiteliol
Hi-A-Vita
|
HMS1921B04
HMS2092L13
HMS501I08
Homagenets Aoral
Homagenets aorl
HSDB 815
Hydrovit A
IDI1_000486
Lard Factor
LMPR01090001
LPK
LS-1578
M.V.C. 9+3
M.V.I.-12
MLS001066379
MLS001074751
MolPort-001-785-962
Mvc Plus
Myvpack
NCGC00091784-01
NCGC00091784-02
NCGC00091784-03
NCGC00091784-04
NCGC00091784-05
NCGC00091784-06
Nio-A-Let
NSC 122759
NSC122759
Oleovitamin A
Ophthalamin
Plivit A
Prepalin
R7632_SIGMA
Retin-11,12-t2-ol (9CI)
retinol
Retinol
RETINOL
Retinol [INN:BAN]
Retinol solution
Retinol-(cellular-retinol-binding-protein)
Retinol, all-trans- (8CI)
Retinolo
Retinolo [DCIT]
Retinolum
Retinolum [INN-Latin]
Retrovitamin A
Ro-a-vit
Rovimix A 500
SDCCGMLS-0066724.P001
Sehkraft A
SMP2_000102
SMR000112036
Solu-A
SPECTRUM1501203
Spectrum5_000993
Spectrum5_001997
ST057232
Super A
Testavol
Testavol S
Thalasphere
trans-retinol
trans-Retinol acid (Vitamin A)
trans-Vitamin A alcohol
tROL
UNII-81G40H8B0T
UNII-G2SH0XKK91
Vaflol
Vafol
Veroftal
Vi-.alpha.
Vi-a
Vi-Alpha
Vi-Dom-A
Vio-A
Vitamin A
Vitamin- A
Vitamin A (Feed)
Vitamin A (USP)
Vitamin A alcohol
Vitamin- A alcohol
Vitamin A alcohol (VAN)
Vitamin- A alcohol solution
Vitamin A cryst
Vitamin A1
Vitamin- A1
Vitamin A1 alcohol
Vitamin A1 alcohol, all trans
Vitamin-?A
Vitamin-?A alcohol
Vitamin-?A alcohol solution
Vitamin-?A1
Vitamine A
Vitaminum A
Vitavel A
Vitavel-A
Vitpex
Vogan
Vogan-Neu
Vogan-nu
Wachstumsvitamin
WLN: L6UTJ A1 B1U1Y1&U2U1Y1&U2Q C1 C1
ZINC03831417
Zinosan N
|
|
32 |
|
tyrosine |
|
Phase 1 |
|
|
|
33 |
|
interferons |
|
Phase 1 |
|
|
|
34 |
|
Antibodies, Blocking |
|
Phase 1 |
|
|
|
35 |
|
Poly I-C |
|
Phase 1 |
|
|
|
36 |
|
Poly ICLC |
|
Phase 1 |
|
|
|
37 |
|
Interferon Inducers |
|
Phase 1 |
|
|
|
38 |
|
Antiviral Agents |
|
Phase 1 |
|
|
|
39 |
|
Pharmaceutical Solutions |
|
Phase 1 |
|
|
|
40 |
|
Angiogenesis Modulating Agents |
|
Phase 1 |
|
|
|
41 |
|
Antimetabolites |
|
Phase 1 |
|
|
|
42 |
|
Anti-Infective Agents |
|
Phase 1 |
|
|
|
43 |
|
Angiogenesis Inhibitors |
|
Phase 1 |
|
|
|
44 |
|
Retinol palmitate |
|
Phase 1 |
|
|
|
45 |
|
retinol |
|
Phase 1 |
|
|
|
46 |
|
Antacids |
|
Not Applicable |
|
|
|
47 |
|
Anticoagulants |
|
Not Applicable |
|
|
|
48 |
|
Gastrointestinal Agents |
|
Not Applicable |
|
|
|
49 |
|
Anti-Ulcer Agents |
|
Not Applicable |
|
|
|
50 |
|
fucoidan |
|
Not Applicable |
|
|
|
Interventional clinical trials:
(show all 13)
# |
Name |
Status |
NCT ID |
Phase |
Drugs |
1 |
Promiseb Topical Cream for Cradle Cap |
Completed |
NCT01214434
|
Phase 4 |
|
2 |
Open-label Study to Evaluate the Safety, PK, and PD of MEK Inhibitor GSK1120212 in Subjects With Relapsed or Refractory Leukemias |
Completed |
NCT00920140
|
Phase 2 |
GSK1120212;GSK1120212 |
3 |
Safety and Efficacy Study for Solid Tumor Patients Treated With Eltrombopag |
Completed |
NCT01147809
|
Phase 2 |
Eltrombopag olamine |
4 |
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL) |
Completed |
NCT01520922
|
Phase 2 |
Bendamustine |
5 |
Study Of Ispinesib In Subjects With Breast Cancer |
Completed |
NCT00089973
|
Phase 2 |
Ispinesib |
6 |
PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma |
Not yet recruiting |
NCT03598816
|
Phase 2 |
Durvalumab;Tremelimumab |
7 |
A Trial To Assess Safety And Tolerability Of PF-04691502 In Cancer Patients |
Completed |
NCT00927823
|
Phase 1 |
PF-04691502 |
8 |
Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia |
Completed |
NCT01351935
|
Phase 1 |
AVL-292 |
9 |
Neoantigen-based Personalized Vaccine Combined With Immune Checkpoint Blockade Therapy in Patients With Newly Diagnosed, Unmethylated Glioblastoma |
Recruiting |
NCT03422094
|
Phase 1 |
|
10 |
Study of S 95005 in Combination With Oxaliplatin in Metastatic Colorectal Cancer |
Recruiting |
NCT02848443
|
Phase 1 |
Trifluridine/tipiracil hydrochloride (S 95005);Oxaliplatin;Bevacizumab;Nivolumab |
11 |
Clinical Study of Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) |
Suspended |
NCT02117336
|
Phase 1 |
P1446A-05 |
12 |
Minimal Residual Disease in Peripheral T-cell Lymphoma |
Recruiting |
NCT03297697
|
|
|
13 |
To Evaluate the QoL Improvement of Oral Oligo Fucoidan in Subjects Receiving Platinum-based Chemotherapy With NSCLC |
Not yet recruiting |
NCT03130829
|
Not Applicable |
|
|